Notice of Effectiveness · EFFECT
MAIA Biotechnology, Inc.
MAIANYSE_AMERICANEQUITYCurrent
Notice of Effectiveness
Company context
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.
Current securities
As-filed source
As filedOpen full document ↗